Q2049 HCPCS Level II code: Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Q2049 is the HCPCS code for “Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Short description: Imported lipodox inj
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2049 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Jul 1, 2012
Where Q2049 sits
- 1Q codesTemporary codes
- 2Active code Q2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q2049 mean?
Q2049 is the HCPCS code for “Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q2049?
CMS lists Q2049’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2049
All Q codesQ2038Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)Q2039Influenza virus vaccine, not otherwise specifiedQ2040Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionQ2041Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2042Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionQ2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mgQ2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per…Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures…